JP2011516846A - 頻拍性不整脈イベントのリスクの予測のためのプロ−エンドセリン−1レベル - Google Patents
頻拍性不整脈イベントのリスクの予測のためのプロ−エンドセリン−1レベル Download PDFInfo
- Publication number
- JP2011516846A JP2011516846A JP2011502391A JP2011502391A JP2011516846A JP 2011516846 A JP2011516846 A JP 2011516846A JP 2011502391 A JP2011502391 A JP 2011502391A JP 2011502391 A JP2011502391 A JP 2011502391A JP 2011516846 A JP2011516846 A JP 2011516846A
- Authority
- JP
- Japan
- Prior art keywords
- proet
- endothelin
- pro
- fragment
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010072272 proendothelin 1 Proteins 0.000 title claims description 37
- 208000001871 Tachycardia Diseases 0.000 title claims description 30
- 206010049447 Tachyarrhythmia Diseases 0.000 title claims description 27
- 238000000034 method Methods 0.000 claims abstract description 31
- 206010019280 Heart failures Diseases 0.000 claims abstract description 10
- 208000019622 heart disease Diseases 0.000 claims abstract description 9
- 238000013517 stratification Methods 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 108010008126 C-terminal proendothelin-1 Proteins 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 30
- 230000003211 malignant effect Effects 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 101800004490 Endothelin-1 Proteins 0.000 claims description 10
- 102400000686 Endothelin-1 Human genes 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 5
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 206010042434 Sudden death Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 230000009862 primary prevention Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 102400001263 NT-proBNP Human genes 0.000 claims description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 2
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 238000000491 multivariate analysis Methods 0.000 claims description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 2
- 238000007473 univariate analysis Methods 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 abstract description 4
- 238000003556 assay Methods 0.000 description 25
- 239000000090 biomarker Substances 0.000 description 17
- 208000030990 Impulse-control disease Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000975 dye Substances 0.000 description 12
- 206010047302 ventricular tachycardia Diseases 0.000 description 10
- 102000002045 Endothelin Human genes 0.000 description 8
- 108050009340 Endothelin Proteins 0.000 description 8
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001325 log-rank test Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 6
- 239000002243 precursor Substances 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- -1 Texas Red Chemical compound 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000369 oxido group Chemical group [*]=O 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
・患者から得られた試料中における、プロ−エンドセリン−1(ProET−1)又は少なくとも12個のアミノ酸のその断片のレベルを決定すること
を含む、前記方法である。
患者、試験計画
当該試験群は、2002年6月〜2003年9月において、Marburg大学の除細動器外来診察室において将来を見越して募集された、虚血性又は非虚血性病因である心不全に罹患している123人の除細動器を有する患者から成った。(Christ et al, Eur J Heart Fail 2007;9:272−9)。本試験は、優良臨床試験基準、及びヘルシンキ宣言の原則に従って行われ、そして患者には本試験への登録前に、インフォームド・コンセントがなされた(Christ et al,Eur J Heart Fail 2007;9:272−9)。
標準化された12リード心電図(ECG)が、各々の患者から、50mm/秒の紙速度で記録され、そして結果を隠された1人の熟練の研究員によって解釈された。50%超の拍動がECG記録の間に測定された場合、ペースメーカー調律を有するように患者が分類された。Vingmed Vivid Five machine(GE Medical Systems,SoHngen,Germany)、及び標準的手順を使用して、呼気期間の最後に、心臓の二次元心エコー画像を得た(Christ et al,Eur J Heart Fail 2007;9:272−9)。
一晩の絶食後、8:30〜10:30の間に、モノベット(monovette)(Sarstedt,Nuembrecht,Germany)を含有するエチレンジアミン四酢酸(EDTA)を使用して、肘正中静脈へと挿入された21ゲージのカニューレを通じて、静脈血試料を採取した。仰臥体位で少なくとも15分間、患者を横たわらせた。EDTA血液試料を速やかに氷上に移動させ、遠心分離を用いて血漿を分離し、そして血漿を分析まで−80℃で貯蔵した。化学発光免疫測定(Bayer AG,Fernwald,Germany)を使用してBNPレベルを決定した。アッセイの分析検出限界は2pg/mLであった。アッセイ内変動係数(CV)は、BNP29.4〜1763pg/mLにおいて1.8〜4.3%であり、そしてアッセイ間CVはBNP29.4〜1736pg/mLにおいて2.3〜4.7%であった(Christ et al,Eur J Heart Fail 2007;9:272−9)。不安定性及び受容体結合のために、エンドセリン−1は測定が困難である。エンドエリン系の活性を間接的に推定する、pre−proET−1の168〜212番目のアミノ酸を対象とする2つのポリクローナル抗体を使用する、新規サンドイッチ免疫測定法(CT−proET−1 LIA,B.R.A.H.M.S AG,Hennigsdorf,Berlin,Germany)(Papassotiriou et al,Clin Chem 2006;52:1144−51)を用いて、C末端ET−1前駆体断片(CT−proET−1)を想定した。アッセイ(正常基準範囲:中央値:44.3,範囲:10.5〜77.4pmol/L)は、0.4pmol/Lの分析検出限界を有し、そしてアッセイ内CVは、値>10pmol/Lに関して、<10%であった(Papassotiriou et al,Clin Chem 2006;52:1144−51)。
非開胸リード系、及び最大ショックエネルギー27〜34Jの2相系ショック波形を有するICDのみが使用された。使用される全てのICDシステムは、装置の動作を引き起こすエピソードの拍動間隔に加えて、蓄積される心内電位図を提供した(Guidant,St.Paul,Minnesota;Medtronic,Minneapolis,Minnesota)。VF検出の時間間隔は、Guidant装置において1〜3秒の範囲であり;Medtronic装置は、VFゾーンに帯電する蓄電器を起動するために、プログラムされた検出サイクル長(範囲240〜280nm)未満で、24拍中18拍を必要とするようにプログラムされた。より遅い心室性頻拍性不整脈が検出され、そして抗頻脈バーストペーシングをし、その後4回までの電気的除細動ショックによって1個又は2個の分離したVT層で処理された(Grimm et al,J Am Coll Cardiol 2002;39:780−7)。
心機能評価及び植え込みデータの結果を含む、ベースライン臨床特性の全てのデータは、Marburg除細動器データベースに将来的に収集された(Christ et al,Eur J Heart Fail 2007;9:272−9,Grimm et al,J Am Coll Cardiol 2002;39:780−7)。バイオマーカー測定時において開始された、本試験における経過観察は60か月までであり、そして登録された患者の全てにおいて完了することができた。装置の照合及び蓄積された心電図の検索のために、自発的ICDショック後、3〜6か月間隔で、又はできる限り早く、患者は最初に、我々の除細動器外来診察室へ行った。熟達した電気生理学者が、ICD療法を始動させる、又は先に記載された基準を使用するのは好適ではないエピソードの、全ての蓄積された心電図を分類した(Christ et al,Eur J Heart Fail 2007;9:272−9;Marchlinski et al,Pacing Clin Electrophysiol 1993;16:527−34)。
連続型変数は、平均±標準偏差(SD)として表現されるか、又は示される通り、中央値(範囲)及び点推定(95%信頼区間)として表現される。第一の目的は、CT−proET−1又はBNPを含むバイオマーカーのレベルが、第一悪性頻拍性不整脈イベントへの時間を予測することに寄与するか否かを調べることであった。悪性頻拍性不整脈は、当該装置によって停止されなければ恐らく死をもたらす、サイクル長≦250ms(心拍数≧240bpm)である、速い心室性頻拍性不整脈(VT又はVF)として定義された(Bocker et al,J Am Coll Cardiol 1993;21:1638−44)。結果測定間の関連性を評価するために、一変量及び多変量Cox比例ハザードモデルが使用された。
全試験コホートの人口学的特性を表1に示す。登録後60か月(中央値51か月)までの最大経過観察の間、27人の患者が第一悪性頻拍性不整脈イベントを発症し、第一悪性頻拍性不整脈イベントを患わない患者(中央値:67pmol/L;p=0.003)と比較して、第一悪性頻拍性不整脈イベントを患う患者においてCT−proET1レベルが有意に増大した(中央値:90pmol/L)。対照的に、BNP群間において違いは見られなかった(p=0.55)(表1)。
悪性頻拍性不整脈は、試験登録後18か月の中央値で生じた(IQR:8〜41か月)。CT−pro−ET−1レベル、NYHAクラス、頸静脈圧の増加、及びベータ遮断薬を用いた治療は、第一エンドポイントを予測する一変量Cox回帰モデルに有意に寄与した。BNP、収縮期血圧、LV拡張終期径、LV−EF、及び左脚ブロック(LBBB)の存在のいずれも、ICD療法を必要とする悪性頻拍性不整脈のリスクを予測しなかった(表2)。ICD患者は、CT−proET−1又はBNPレベルに従って、2つの群に層別化され、そしてKaplan Meier分析が行われた。頻拍性不整脈のリスクは、CT−proET−1血漿レベル>73pmol/L(中央値)の患者が、CT−proET−1値がこのカットポイント未満である患者よりも有意に高かった(logrank検定,p<0.001,図1A)。エンドポイントとして悪性頻拍性不整脈を使用したとき、BNP血漿レベル≦83pg/mL(中央値)又は>183pg/mLの患者において違いは見られなかった(logrank検定,p=0.10p,図1B)。LV駆出分画とCT−proET−1レベルとの有意な関連性は見られなかった(図2)。
Claims (12)
- 心疾患を患う患者のための、悪性頻拍性不整脈の発症のインビトロにおけるリスク層別化方法であって:
・患者から得られた試料中における、プロ−エンドセリン−1(ProET−1)又は少なくとも12個のアミノ酸のその断片のレベルを決定すること
を含む、前記方法。 - プロ−エンドセリン−1(ProET−1)、又は少なくとも12個のアミノ酸のその断片の前記レベルが、植え込み型除細動器(ICD)、及び/又は抗不整脈性ハイブリッド療法を必要とする悪性頻拍性不整脈のリスクと相関性がある、請求項1に記載のインビトロにおける方法。
- 不整脈による突然死の第一次予防のための、請求項2に記載のインビトロにおける方法。
- 前記相関性ステップが、プロ−エンドセリン−1(ProET−1)、又は少なくとも12個のアミノ酸のその断片の前記レベルと閾値とを比較することを含み、そしてそれにより、プロ−エンドセリン−1(ProET−1)、又は少なくとも12個のアミノ酸のその断片、又はそれらの断片の前記レベルが、前記閾値レベルを超えているとき、前記患者は頻拍性不整脈の高リスク状態にある、請求項2又は3に記載の方法。
- CT−proET−1がプロ−エンドセリン−1(ProET−1)断片として使用される場合、前記閾値が約73+/−20%pmol/Lである、請求項4に記載の方法。
- 前記心疾患が、虚血性又は非虚血性病因のいずれかの心不全である、請求項1〜5のいずれか一項に記載の方法。
- 前記患者がLV駆出分画≦45%を有する、請求項1〜6のいずれか一項に記載の方法。
- 前記試料が血液試料、血清試料、及び血漿試料を含む群から選択される、請求項1〜7のいずれか一項に記載の方法。
- プロ−エンドセリン−1(ProET−1)、又は少なくとも12個のアミノ酸のその断片の前記レベルを、1つ以上の追加の予後マーカー、パラメーター、又は因子のレベル/条件と組み合わせることをさらに含み、それにより、プロ−エンドセリン−1(ProET−1)、又は少なくとも12個のアミノ酸のその断片と、追加の予後マーカー(単数又は複数)、パラメーター(単数又は複数)、又は因子(単数又は複数)の前記レベル/条件との組み合わせが、前記方法のリスクに関する予測値を増加させる、請求項1〜8のいずれか一項に記載の方法。
- 前記追加の予後マーカー、パラメーター、又は因子が、表2に列挙された全てのパラメーターを含む群から選択され、そしてそれは一変量又は多変量分析においてp<0.05を示し、それによりBNPは、proBNP又は、BNP若しくはNT−proBNPを含む、少なくとも12個のアミノ酸のその断片に関する一例に過ぎない、請求項9に記載の方法。
- プロ−エンドセリン−1(ProET−1)又は少なくとも12個のアミノ酸のその断片の前記レベルが、サンドイッチ免疫測定法を用いて測定される、請求項1〜10のいずれか一項に記載の方法。
- 前記プロ−エンドセリン−1の断片がCT−pro−ET−1である、請求項1〜10のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08154109.6 | 2008-04-04 | ||
EP08154109A EP2107377A1 (en) | 2008-04-04 | 2008-04-04 | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
PCT/EP2009/053995 WO2009121951A1 (en) | 2008-04-04 | 2009-04-03 | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011516846A true JP2011516846A (ja) | 2011-05-26 |
JP5442712B2 JP5442712B2 (ja) | 2014-03-12 |
Family
ID=39471708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502391A Active JP5442712B2 (ja) | 2008-04-04 | 2009-04-03 | 頻拍性不整脈イベントのリスクの予測のためのプロ−エンドセリン−1レベル |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110111525A1 (ja) |
EP (2) | EP2107377A1 (ja) |
JP (1) | JP5442712B2 (ja) |
CN (1) | CN101984766B (ja) |
ES (1) | ES2464119T3 (ja) |
HK (1) | HK1153538A1 (ja) |
WO (1) | WO2009121951A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015520371A (ja) * | 2012-05-18 | 2015-07-16 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
CA3086149A1 (en) | 2006-04-04 | 2007-10-11 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
EP3358354B1 (en) | 2008-01-18 | 2020-07-15 | President and Fellows of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
BR112013001752A2 (pt) | 2010-07-23 | 2016-05-31 | Harvard College | método de detectar doenças ou condições usando células fagocídicas |
US20130210647A1 (en) | 2010-07-23 | 2013-08-15 | President And Fellows Of Harvard College | Methods of Detecting Cardiovascular Diseases or Conditions |
WO2012012694A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
BR112013001754A2 (pt) | 2010-07-23 | 2016-05-31 | Harvard College | método para detectar marcas de doença ou condições em fluídos corpóreos |
EP2596353A4 (en) | 2010-07-23 | 2014-01-15 | Harvard College | METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING |
US8838224B2 (en) * | 2012-03-30 | 2014-09-16 | General Electric Company | Method, apparatus and computer program product for predicting ventricular tachyarrhythmias |
CA2876731A1 (en) | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
WO2013188828A1 (en) | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
US8521269B1 (en) | 2012-06-27 | 2013-08-27 | Medtronic, Inc. | Determining tachyarrhythmia detection parameters based on prior detected episodes |
US20140206632A1 (en) * | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
EP3693742B1 (en) | 2014-09-11 | 2022-04-06 | Harry Stylli | Methods of detecting prostate cancer |
WO2016183683A1 (en) * | 2015-05-20 | 2016-11-24 | University Health Network | Method and system for assessing qrs components and the risk of ventricular arrhythmias |
US11925467B2 (en) | 2018-05-04 | 2024-03-12 | University Health Network | System and method for assessing QRS components and likelihood of response to cardiac resynchronization therapy |
CA3124744A1 (en) * | 2019-03-29 | 2020-10-08 | B.R.A.H.M.S Gmbh | Prescription of remote patient management based on biomarkers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007062676A1 (en) * | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
JP2007523324A (ja) * | 2004-02-05 | 2007-08-16 | メドトロニック・インコーポレーテッド | 命にかかわる不整脈のリスク状態にある患者を識別する方法及び装置 |
WO2007144194A1 (de) * | 2006-06-16 | 2007-12-21 | B.R.A.H.M.S Aktiengesellschaft | In vitro multiparameter-bestimmungsverf ahren zur diagnose und frühdiagnose von neurodegenerativen erkrankungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
IL121659A (en) * | 1996-10-25 | 2000-07-16 | Bayer Ag | Method for determining CPSA in a blood sample |
WO1998035707A1 (en) * | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
-
2008
- 2008-04-04 EP EP08154109A patent/EP2107377A1/en not_active Withdrawn
-
2009
- 2009-04-03 WO PCT/EP2009/053995 patent/WO2009121951A1/en active Application Filing
- 2009-04-03 CN CN200980110844.9A patent/CN101984766B/zh active Active
- 2009-04-03 EP EP09727643.0A patent/EP2260307B1/en active Active
- 2009-04-03 ES ES09727643.0T patent/ES2464119T3/es active Active
- 2009-04-03 US US12/935,960 patent/US20110111525A1/en not_active Abandoned
- 2009-04-03 JP JP2011502391A patent/JP5442712B2/ja active Active
-
2011
- 2011-07-22 HK HK11107630.8A patent/HK1153538A1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007523324A (ja) * | 2004-02-05 | 2007-08-16 | メドトロニック・インコーポレーテッド | 命にかかわる不整脈のリスク状態にある患者を識別する方法及び装置 |
WO2007062676A1 (en) * | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
WO2007144194A1 (de) * | 2006-06-16 | 2007-12-21 | B.R.A.H.M.S Aktiengesellschaft | In vitro multiparameter-bestimmungsverf ahren zur diagnose und frühdiagnose von neurodegenerativen erkrankungen |
Non-Patent Citations (8)
Title |
---|
JPN5011011581; SZUCS ANDREA: 'EFFECT OF INCESSANT VENTRICULAR TACHYARRHYTHMIAS ON SERUM ENDOTHELIN AND BIG-ENDOTHELIN LEVELS' JOURNAL OF CARDIOVASCULAR PHARMACOLOGY V44 SUPPL.1, 20041101, P.S402-S406 * |
JPN5011011583; ALEXIOU KONSTANTIN: 'ARRHYTHMOGENIC EFFECTS INDUCED BY CORONARY CONVERSION OF PULMONARY BIG ENDOTHELIN 以下備考' JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY V32 N6, 19981115, P1773-1778 * |
JPN5011011585; BARGER RUDOLF: 'B-TYPE NATRIURETIC PEPTIDE PREDICTS SUDDEN DEATH IN PATIENTS WITH CHRONIC HEART FAILURE' CIRCULATION V105 N20, 20020521, P2392-2397 * |
JPN6013011231; J Card Fail Vol.12, No.5, Page.375-380, 2006 * |
JPN6013011233; Life Sci Vol.79, No.19, Page.1812-1819, 2006 * |
JPN6013011235; Mol Med Vol.41, No.7, Page.812-819, 2004 * |
JPN6013011236; J Arrhythmia Vol.23, No.Supplement, Page.183 98, 2007 * |
JPN6013011238; Jpn Circ J Vol.65, No.Supplement 1-A, 2001, Page.447 PJ325 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015520371A (ja) * | 2012-05-18 | 2015-07-16 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 |
US10408845B2 (en) | 2012-05-18 | 2019-09-10 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
US11340236B2 (en) | 2012-05-18 | 2022-05-24 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
Also Published As
Publication number | Publication date |
---|---|
JP5442712B2 (ja) | 2014-03-12 |
WO2009121951A1 (en) | 2009-10-08 |
US20110111525A1 (en) | 2011-05-12 |
ES2464119T3 (es) | 2014-05-30 |
CN101984766B (zh) | 2015-05-13 |
EP2260307A1 (en) | 2010-12-15 |
EP2107377A1 (en) | 2009-10-07 |
HK1153538A1 (en) | 2012-03-30 |
CN101984766A (zh) | 2011-03-09 |
EP2260307B1 (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5442712B2 (ja) | 頻拍性不整脈イベントのリスクの予測のためのプロ−エンドセリン−1レベル | |
EP2470911B1 (en) | Galectin-3 and cardiac resynchronization therapy | |
JP7157045B2 (ja) | 心房細動と脳卒中の評価における循環esm-1(エンドカン) | |
RU2613885C2 (ru) | Биомаркеры для диагностики, прогноза, оценки и стратификации терапии обмороков | |
CN109328303B (zh) | 用于预测心房纤颤的复发的循环血管生成素-2 (Ang-2) | |
US20200116708A1 (en) | Fatty acid binding protein 3 for the assessment of atrial fibrillation (af) | |
JP2021534430A (ja) | 心房細動の評価における循環bmp10(骨形成タンパク質10) | |
BR112021003317A2 (pt) | métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para melhorar a precisão da previsão de uma pontuação de risco clínico de acidente vascular cerebral e para auxiliar na avaliação da fibrilação atrial, método implementado por computador para avaliar a fibrilação atrial, kit e uso in vitro | |
US9128103B2 (en) | Mid-regional pro-atrial natriuretic peptide (pro-ANP) for the identification of patients with atrial fibrillation with an onset of less than 48 hours ago | |
JP7333384B2 (ja) | 心房細動の評価における循環spon-1(スポンジン-1) | |
JP7419341B2 (ja) | 心房細動の評価における循環DKK3(Dickkopf関連タンパク質3) | |
CN113302497A (zh) | 循环tfpi-2(组织因子途径抑制剂2)在心房颤动和抗凝治疗评定中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111115 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130725 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5442712 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |